Uttar Pradesh Bans Coldrif Cough Syrup Amid Deaths in Madhya Pradesh
The Uttar Pradesh government has imposed an immediate ban on the sale and distribution of Coldrif cough syrup after reports linked the medication to 14 deaths in Madhya Pradesh. This decision has sparked widespread concern over drug safety and regulatory oversight in India.
Tragic Incidents in Madhya Pradesh
Health authorities in Madhya Pradesh reported a series of deaths in Ujjain and Indore, primarily affecting children and elderly patients. Investigations revealed that all victims had consumed Coldrif cough syrup prior to their deaths. Lab tests allegedly detected toxic substances, including high levels of diethylene glycol, a chemical used in antifreeze, in the syrup.
Diethylene glycol is a dangerous toxin that can cause kidney failure, neurological damage, and death. Its presence in medicines is strictly prohibited, but past incidents of contamination have raised red flags in India and globally. The Madhya Pradesh government has launched a criminal investigation to hold manufacturers and distributors accountable.
Uttar Pradesh’s Proactive Ban
Uttar Pradesh Health Minister Dr. Mahesh Sharma announced the ban, stating, “The safety of our citizens is our top priority. We cannot take risks when lives are at stake. The ban will remain until a thorough investigation confirms the product’s safety.”
Manufacturer’s Response
The Gujarat-based manufacturer of Coldrif denied any wrongdoing, asserting that their products undergo rigorous quality checks and comply with regulatory standards. In a press release, the company expressed sadness over the deaths but maintained that their product was not the cause.
Regulatory Concerns
This incident has reignited debates about India’s drug regulatory framework. Despite being a global leader in generic medicine production, the country has faced criticism for lax enforcement of quality standards. In 2020, the WHO warned about Indian-made cough syrups after similar contamination cases abroad.
Calls for Stricter Measures
Public health experts are urging the government to enhance drug safety protocols. Dr. Anjali Rao, a pharmacologist, emphasized the need for stricter monitoring, better infrastructure, and harsher penalties for violators.
Victims’ Families Demand Justice
Families of the victims in Madhya Pradesh are demanding accountability, claiming they were unaware of the risks associated with the syrup, which was prescribed by local doctors and purchased from trusted pharmacies.
A Grim Reminder
The Coldrif case highlights the critical need for robust drug safety mechanisms. While Uttar Pradesh’s ban is a positive step, coordinated efforts between central and state governments are essential to prevent future tragedies and restore public trust in the healthcare system.
Stay updated on this developing story with NextMinuteNews.
